Prism Pharmaceuticals Raises $68 Million to Advance Acute
Care Portfolio
Prism Pharmaceuticals, Inc. has secured up to $68 million
in capital from Paul Capital Partners' Paul Royalty Fund
II, L.P. and existing investor Essex Woodlands Health Ventures
Fund VI.
learn more>
|